Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice

Clinical and Experimental Immunology

Volumn 162, Issue 3, 2010, Pages 568-577

  Rearte, B ^a   Maglioco, A ^a   Balboa, L ^b   Bruzzo, J ^a   Landoni, V I ^a   Laborde, E A ^a   Chiarella, P ^a   Ruggiero, R A ^a   Fernandez G C ^a   Isturiz, M A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

Endotoxin tolerance; Glucocorticoids; Immunosuppression; RU486

Indexed keywords

CD11B ANTIGEN; CYCLOPHOSPHAMIDE; ENDOTOXIN; GEMCITABINE; GLUCOCORTICOID; LIPOPOLYSACCHARIDE; MIFEPRISTONE; TRANSCRIPTION FACTOR FOXP3; DEOXYCYTIDINE; DRUG DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GLUCOCORTICOID RECEPTOR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PATHOLOGY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MIFEPRISTONE; RECEPTORS, GLUCOCORTICOID; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79952474186     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04262.x     Document Type: Article

References (58)

1. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. J Trauma 2005; 58:867-74.
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-24.
3. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15:496-7.
4. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
5. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009; 101:36-47.
6. Wang TS, Deng JC. Molecular and cellular aspects of sepsis-induced immunosuppression. J Mol Med 2008; 86:495-506.
7. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30:475-87.
8. Lyn-Kew K, Standiford TJ. Immunosuppression in sepsis. Curr Pharm Des 2008; 14:1870-81.
9. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001; 16:83-96.
10. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006; 177:1967-74.
11. Wiersinga WJ, van't Veer C, van den Pangaart PS et al. Immuno-suppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit Care Med 2009; 37:569-76.
12. Limaye AP, Kirby KA, Rubenfeld GD et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300:413-22.
13. Luyt CE, Combes A, Deback C et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175:935-42.
14. Carroll JA, Reuter RR, Chase CC et al. Profile of the bovine acute-phase response following an intravenous bolus-dose lipopolysaccharide challenge. Innate Immun 2009; 15:81-9.
15. Fock RA, Vinolo MA, Crisma AR, Nakajima K, Rogero MM, Borelli P. Protein-energy malnutrition modifies the production of interleukin-10 in response to lipopolysaccharide (LPS) in a murine model. J Nutr Sci Vitaminol (Tokyo) 2008; 54:371-7.
16. Sanchez-Lemus E, Benicky J, Pavel J, Saavedra JM. In vivo Angiotensin II AT(1) receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 2009; 23:945-57.
17. Beishuizen A, Thijs LG. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003; 9:3-24.
18. Evans GF, Zuckerman SH. Glucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 1991; 21:1973-9.
19. Cavaillon JM. The nonspecific nature of endotoxin tolerance. Trends Microbiol 1995; 3:320-4.
20. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Endotoxin tolerance: is there a clinical relevance? J Endotoxin Res 2003; 9:101-7.
21. ParrilloJE. Pathogeneticmechanismsofsepticshock. N Engl J Med 1993; 328:1471-7.
22. West MA, Heagy W. Endotoxin tolerance: a review. Crit Care Med 2002; 30:S64-73.
23. Morrison DC, Silverstein R, Luchi M, Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect Dis Clin North Am 1999; 13:313-40.
24. Vasilescu C, Olteanu M, Flondor P. How relevant are in vivo and in vitro studies for clinical sepsis? A mathematical model of LPS signaling based on endotoxin tolerance. Chirurgia (Bucur) 2009; 104:195-201.
25. Rearte B, Landoni V, Laborde E, Fernandez G, Isturiz M. Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance. Clin Exp Immunol 2010; 159:208-16.
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74.
27. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176:2085-94.
28. Scumpia PO, Delano MJ, Kelly KM et al. Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol 2006; 177:7943-9.
29. Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34:336-44.
30. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21.
31. National Institutes of Health. Guide for the care and use of laboratory animals. NIH Publication no. 85-23. Bethesda, MD: National Institutes of Health, 1985.
32. Chiarella P, Vulcano M, Bruzzo J et al. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 2008; 57:701-18.
33. Benjamim CF, Hogaboam CM, Kunkel SL. The chronic consequences of severe sepsis. J Leukoc Biol 2004; 75:408-12.
34. Yadavalli GK, Auletta JJ, Gould MP, Salata RA, Lee JH, Heinzel FP. Deactivation of the innate cellular immune response following endotoxic and surgical injury. Exp Mol Pathol 2001; 71:209-21.
35. Delano MJ, Scumpia PO, Weinstein JS et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204:1463-74.
36. Varga G, Ehrchen J, Tsianakas A et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008; 84:644-50.
37. Chang CP, Wang SW, Huang ZL et al. Non-genomic rapid inhibition of Na+/H+-exchange 1 and apoptotic immunosuppression in human T cells by glucocorticoids. J Cell Physiol 2010; 223:679-86.
38. Ma J, Xie Y, Shi Y, Qin W, Zhao B, Jin Y. Glucocorticoid-induced apoptosis requires FOXO3A activity. Biochem Biophys Res Commun 2008; 377:894-8.
39. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166:5398-406.
40. Linehan DC, Goedegebuure PS. CD25+ CD4+ regulatory T-cells in cancer. Immunol Res 2005; 32:155-68.
41. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3:169-76.
42. Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678-81.
43. Allary J, Annane D. Glucocorticoids and sepsis. Minerva Anestesiol 2005; 71:759-68.
44. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 1997; 18:418-24.
45. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11(Suppl. 1): S45-55.
46. Muenzer JT, Davis CG, Chang K et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 2010; 78:1582-92.
47. Forte N, Lombardi L, Paradisi F. The influence of in vivo pretreatment of cyclophosphamide on phagocytic activity of mouse macrophages in vitro. Ric Clin Lab 1983; 13:367-71.
48. Giordano M, Isturiz MA. Enhancement of erythrophagocytosis by cyclophosphamide. Cell Immunol 1983; 81:187-91.
49. Artym J, Zimecki M, Kruzel M. Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice. Med Sci Monit 2004; 10:BR84-9.
50. Barrat FJ, Cua DJ, Boonstra A et al. In vitro generation of interleukin 10-producing regulatory CD4(+)Tcellsisinducedbyimmunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195:603-16.
51. Chaudhuri D, Suriano R, Mittelman A, Tiwari RK. Targeting the immune system in cancer. Curr Pharm Biotechnol 2009; 10:166-84.
52. Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007; 6:880-5.
53. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102:115-23.
54. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62:2353-8.
55. Sabbele NR, Van Oudenaren A, Benner R. The effect of cyclophosphamide on B cells and `background' immunoglobulin-secreting cells in mice. Immunopharmacology 1988; 15:21-30.
56. Deng JC, Cheng G, Newstead MW et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 2006; 116:2532-42.
57. Escoll P, del Fresno C, Garcia L et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun 2003; 311:465-72.
58. Broad A, Jones DE, Kirby JA. Toll-like receptor (TLR) response tolerance: a key physiological 'damage limitation' effect and an important potential opportunity for therapy. Curr Med Chem 2006; 13:2487-502.